December - 2018

MECFA Blog

Proteostasis Therapeutics Provides Clinical Enrollment Update

BOSTON, Dec. 20, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated...

Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections

Aridis Pharmaceuticals has enrolled the first healthy participant in its Phase 1/2a clinical trial to evaluate the antibacterial...

Specific Sweat Test Better Detects Kalydeco’s Effects on CFTR Function, Study Suggests

The effects of CFTR modulator therapies such as Kalydeco (ivacaftor) can be more reliably assessed using a test that specifically...

Phase 3 Trial of RDEB Therapy EB-101 to Start in 2019, Abeona Therapeutics Says

Abeona Therapeutics plans to start a Phase 3 trial in 2019 testing the cell therapy candidate EB-101 as a treatment for recessive...

People with Rare Diseases Are Humans, Not Commodities

If you keep up with CF research, you may have seen the news about Phase 3 of the triple combination Vertex therapies. In these results,...

Triple Combo Treatment Improves Lung Function in Patients with Cystic Fibrosis

An investigational triple combination treatment regimen for cystic fibrosis (CF) improved patients’ lung function in 2 phase 3 studies,...

NuvoAir Redefines Home Monitoring for Cystic Fibrosis Patients

STOCKHOLM--(BUSINESS WIRE)--Dec 4, 2018--THE FINDINGS from a pilot study into a new way of caring for those with cystic fibrosis (CF)...

Mucus Protects Lungs by Forming Layers, Preventing Worsening of Lung Diseases, Studies Reveal

Two new studies highlight the important role of mucus in cleaning and protecting the lungs, and how its accumulation and impaired...

Study Reveals How Cystic Fibrosis Affects Young Women’s Sexual Health

Girls with cystic fibrosis (CF) reach puberty six to eight months later than healthy girls, about 16 percent of young females with CF...

PARI Devices used in SHIP Study of Hypertonic Saline in Preschoolers with Cystic Fibrosis

MIDLOTHIAN, Va., Nov. 29, 2018 /PRNewswire/ -- A recent study in preschoolers with cystic fibrosis (CF) conducted by Cystic Fibrosis...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p